我国医药上市公司研发资金投入强度影响因素的实证研究——基于A股上市公司面板数据

发布时间：2018-04-12 17:27

本文选题：医药上市公司 + 研发资金投入强度　；参考：《科技管理研究》2017年16期

【摘要】：基于2011—2015年我国医药上市公司年报数据,运用STATA 14.0进行面板回归分析,实证分析资本结构、企业规模、股权结构、研发人员投入、研发知识产出等因素对医药上市公司研发资金投入强度的影响,为提升医药上市公司研发投入水平提供参考。结果显示,企业规模、股权结构中股权制衡度、研发人员投入、研发知识产出均与医药上市公司研发资金投入强度呈显著正相关关系,资本结构、股权结构中股权集中度均与医药上市公司研发资金投入强度无显著相关关系。通过适当的扩大企业规模、增加研发人员投入、完善专利保护制度,促进研发成果高效率转化、合理分配股权结构等手段提高我国医药上市公司研发资金投入水平。
[Abstract]:Based on the annual report data of Chinese pharmaceutical listed companies from 2011 to 2015, using STATA 14.0 to carry out panel regression analysis, empirical analysis of capital structure, enterprise size, equity structure, R & D personnel input,The effect of R & D knowledge output on R & D investment intensity of pharmaceutical listed companies provides a reference for improving R D investment level of pharmaceutical listed companies.The results show that the scale of the enterprise, the degree of equity balance in the ownership structure, the input of R & D personnel, the output of R & D knowledge are positively correlated with the intensity of R & D investment of listed pharmaceutical companies, and the capital structure.There is no significant correlation between ownership concentration and R & D investment intensity of pharmaceutical listed companies.Through the appropriate expansion of enterprise size, increase R & D personnel input, improve the patent protection system, promote the efficient transformation of R & D results, reasonable allocation of equity structure and other means to improve the level of R & D investment of listed pharmaceutical companies in China.
【作者单位】：沈阳药科大学工商管理学院;
【基金】：科技部“十二五”重大新药创制国家科技重大专项“辽宁省国家重大新药创制综合平台——基于信息管理的新药研发风险控制技术”(No.2013ZX09301305)
【分类号】：F273.1;F406.7;F426.72

【相似文献】